News - BIOQuébec

7 July 2026
PQE Group Announces Release of 2025 Sustainability Report
PQE Group is pleased to announce it has completed and released its 2025 Sustainability Report…
Read more
7 July 2026
Québec is the first province to list PrOKEDIMC on the public drug reimbursement formulary for the treatment of schizophrenia
Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), announces the listing…
Read more
7 July 2026
Pitch your next-generation immunotherapy innovation to experts from leading global pharmaceutical companies on September 16, 2026!
We are seeking ambitious next-generation immunotherapy innovations with strong…
Read more
7 July 2026
Funding Opportunity to Support Innovation in Quebec’s Biopharma Sector!
SynergiQc, our biopharmaceutical R&D funding program, is designed to support innovation…
Read more
7 July 2026
Funding for five RNA innovation projects
CQDM is proud to announce the funding of five projects led by companies…
Read more
7 July 2026
Announcement of a nearly $11 million contribution from the Government of Quebec to AReNA, Québec’s RNA Hub
At the opening of the Québec Pavilion at the 2026 BIO International Convention…
Read more

Québec Becomes First Province to Cover TRYNGOLZA® (olezarsen) for Familial Chylomicronemia Syndrome

Quebec is the first Canadian province to list TRYNGOLZA® (olezarsen) on the drug formulary of its public drug insurance plan.